FDA approves new treatment Xeljanz (tofacitinib) for moderately to severely active ulcerative colitis
FDA approves new treatment Xeljanz (tofacitinib) for moderately to severely active ulcerative colitis
FDA approves new treatment for moderately to severely active ulcerative colitisThe U.S. Food and Drug Administration today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis. Xeljanz is the first oral medication approved for chronic use in this indication. Other FDA-approved treatments for the chronic treatment of…
View On WordPress












